Literature DB >> 3118674

Gadolinium-DTPA and MR imaging of pituitary adenoma: a preliminary report.

P C Davis1, J C Hoffman, J A Malko, G T Tindall, Y Takei, L Avruch, I F Braun.   

Abstract

Gadolinium-DTPA MR imaging (Gd-MR), unenhanced MR imaging, and contrast-enhanced CT studies were compared prospectively in six patients with surgically confirmed pituitary adenomas and three patients without sellar pathology to determine the utility of Gd-MR in the diagnosis of pituitary adenoma. In normal patients, the pituitary gland, cavernous sinus, and infundibulum enhanced by T1 shortening after gadolinium. In adenoma patients, two of four focal lesions identified with contrast-enhanced CT were identified with Gd-MR, and one was identified with unenhanced MR. The earliest short repetition-time sequence performed after gadolinium injection was best for focal lesion detection. Normal cavernous sinus enhancement by gadolinium made identification of cavernous sinus extension of adenoma difficult. Infundibulum displacement was better seen with contrast-enhanced CT (two vs one); however, unenhanced and Gd-MR were better than contrast-enhanced CT for demonstrating chiasmal compression (four vs three). Contrast-enhanced CT, Gd-MR, and plain MR were equally able to identify gland enlargement, sellar floor erosion, and abnormalities of the diaphragma sellae. In this preliminary series, we found Gd-MR to be promising for imaging adenomas; however, modifications in Gd-MR technique including thinner slices and immediate scanning after gadolinium injection are necessary for the best detection of focal lesions.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3118674      PMCID: PMC8334501     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  9 in total

Review 1.  Brain imaging.

Authors:  R I Grossman
Journal:  AJNR Am J Neuroradiol       Date:  2000-01       Impact factor: 3.825

2.  Contrast behavior between microadenoma and normal pituitary gland after gadolinium injection as a function of time at 1.5 T.

Authors:  T Stadnik; A Stevenaert; A Beckers; D Van Herzele; R Luypaert; T Buisseret; M Osteaux
Journal:  Neuroradiology       Date:  1992       Impact factor: 2.804

3.  Pituitary microadenomas. Does Gadolinium enhance their demonstration?

Authors:  P Macpherson; D M Hadley; E Teasdale; G Teasdale
Journal:  Neuroradiology       Date:  1989       Impact factor: 2.804

4.  The effect of MR contrast medium dose on pituitary gland enhancement, microlesion enhancement and pituitary gland-to-lesion contrast conspicuity.

Authors:  Walter S Bartynski; John F Boardman; Stephen Z Grahovac
Journal:  Neuroradiology       Date:  2006-05-03       Impact factor: 2.804

Review 5.  Magnetic resonance imaging of pituitary adenomas.

Authors:  Jean-François Bonneville; Fabrice Bonneville; Françoise Cattin
Journal:  Eur Radiol       Date:  2004-12-31       Impact factor: 5.315

6.  The value of paramagnetic contrast agent gadolinium-DTPA in the diagnosis of pituitary adenomas.

Authors:  T Nakamura; W Schörner; R C Bittner; R Felix
Journal:  Neuroradiology       Date:  1988       Impact factor: 2.804

7.  Potential utility of FLAIR in MRI-negative Cushing's disease.

Authors:  Grégoire P Chatain; Nicholas Patronas; James G Smirniotopoulos; Martin Piazza; Sarah Benzo; Abhik Ray-Chaudhury; Susmeeta Sharma; Maya Lodish; Lynnette Nieman; Constantine A Stratakis; Prashant Chittiboina
Journal:  J Neurosurg       Date:  2017-10-13       Impact factor: 5.115

8.  The value of three-dimensional turbo-FLASH and spin-echo sequences in the detection of pituitary microadenomas following gadolinium administration.

Authors:  T Stadnik; J D'Haens; R Luypaert; M Osteaux
Journal:  Neuroradiology       Date:  1994-11       Impact factor: 2.804

9.  Assessment of t2-weighted coronal magnetic resonance images in the investigation of pituitary lesions.

Authors:  Ruken Yuksekkaya; Levent Aggunlu; Yusuf Oner; Halil Celik; Sergin Akpek; Fatih Celikyay
Journal:  ISRN Radiol       Date:  2014-03-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.